Amylin and Biocon to develop peptide therapeutic
This article was originally published in Scrip
Executive Summary
The biotech companies, Biocon and Amylin Pharmaceuticals have entered into an agreement to jointly develop, manufacture and commercialise a novel peptide therapeutic for the potential treatment of diabetes.